CTLA4 and neoplasm: Moreover, double ICI combination, anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) agent, and anti-PD-1 agent combination therapy presented promising anti-tumor efficacy in MSI-H/dMMR mCRC (5, 6).